Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
36.12 EUR | +0.35% |
|
-0.68% | -14.38% |
06-06 | Jefferies lowers target for Dermapharm to 51 euros - 'Buy' | DP |
06-06 | DERMAPHARM : Jefferies reiterates its Buy rating | ZD |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Sales forecast by analysts have been recently revised upwards.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- The group shows a rather high level of debt in proportion to its EBITDA.
- The company appears highly valued given the size of its balance sheet.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-14.38% | 2.08B | B- | ||
+52.93% | 803B | C+ | ||
+41.25% | 631B | B | ||
-7.08% | 351B | C+ | ||
+17.40% | 324B | B- | ||
+10.58% | 303B | C+ | ||
+16.72% | 243B | B+ | ||
+2.17% | 228B | A+ | ||
+10.27% | 217B | B- | ||
+6.24% | 164B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- DMP Stock
- Ratings Dermapharm Holding SE